Heart Failure Research

Heart failure, also known as congestive heart failure or CHF, is an inability of the heart to pump sufficient blood around the body.Heart failure typically occurs secondary to an existing pathology that alters cardiac function. Examples of syndromes that can precede heart failure include myocardial infarction, arrhythmia or infection. These can also cause dilated cardiomyopathy, a condition which accounts for approximately one third of all cases of heart failure. The pathogenesis of heart failure is cyclical and progressive; endogenous mechanisms, which are activated during heart failure in an attempt to counteract the symptoms, actually worsen cardiac function. Cardiac dysfunction, either systolic or diastolic, triggers a decrease in stroke volume and a resultant increase in cardiac output. In healthy individuals the body responds to decreases in cardiac output by initiating the renin-angiotensin-aldosterone system (RAAS) to promote fluid retention, and also by activating the sympathetic nervous system to cause peripheral vasoconstriction. Under normal circumstances this counteracts the imbalance in stroke volume, restoring cardiac output to normal levels. In patients with heart failure the increase in blood volume, together with the heightened peripheral resistance and elevated levels of circulating catecholamines, causes an increased load on the already weakened ventricles with each contraction, and the stroke volume does not return to normal levels. Repeated cycles of this process further weaken the ventricle walls, prompting ventricular hypertrophy and a decreased force of contraction.

Heart Failure Research Products Targets

Products for Heart Failure Research - Page 9

  1. Cat.No. Product Name Information/Activity
  2. BCC4366 Spironolactone Spironolactone is a potent antagonist of the androgen receptor. Spironolactone chemical structure
  3. BCC1119 Bumetanide Bumetanide (Ro 10-6338;PF 1593) is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively. Bumetanide chemical structure
  4. BCC3782 Furosemide Furosemide is a loop diuretic inhibitor of Na+/2Cl-/K+ (NKCC) cotransporter of which used in the treatment of congestive heart failure and edema. Furosemide chemical structure
  5. BCC3715 A66 A66 is a highly specific and selective p110α inhibitor with an IC50 of 32 nM. A66 chemical structure
  6. BCC4988 AS-252424 AS-252424 is a potent and selective PI3Kγ inhibitor with an IC50 of 30±10 nM. AS-252424 chemical structure
  7. BCC2495 AS-605240 AS-605240 is a specific and orally active inhibitor of the PI3Kγ, with an IC50 of 8 nM, and a Ki of 7.8 nM. AS-605240 chemical structure
  8. BCC2523 AZD6482 AZD 6482 (KIN-193) is a potent and selective p110β inhibitor with an IC50 of 0.69 nM. AZD6482 chemical structure
  9. BCC1813 NVP-BAG956 NVP-BAG956 is an ATP-competitive PI3K inhibitor with IC50s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively. NVP-BAG956 chemical structure
  10. BCC1507 CZC24832 CZC24832 is a highly selective and potent PI3Kγ inhibitor (IC50=27 nM) with apparent dissociation constants (Kdapp) of 19 nM. CZC24832 chemical structure
  11. BCC4984 GSK1059615 GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. GSK1059615 chemical structure

Items 81 to 90 of 148 total